• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    Diseases of the Esophagus

    Diseases of the Esophagus

    JournalISSN 1120-8694eISSN 1442-2050中科院 医学 4区

    年发文量

    研究主题

    论文(7382)

    排序
    1What the EUROSTAR Consensus Tells Us about Symptom Management and Survivorship after Esophago-Gastric Resection
    Ewen A Griffiths,Jane M Blazeby
    2026
    引用
    AI阅读
    加入学术空间
    2Detection of Barrett’s Esophagus Through Exhaled Breath Using an Electronic Nose Device: a Multicenter Validation Study
    Lotte J Huibertse,Yonne Peters,Ruud W M Schrauwen,Adriaan C I T L Tan, Niek Warringa,Jordy P W Burger,Peter D Siersema

    Summary Esophageal adenocarcinoma incidence has risen dramatically in the Western world over the past 30 years, particularly driven by gastroesophageal reflux disease (GERD) and Barrett’s esophagus (BE). We aimed to assess whether Volatile Organic Compound (VOC) breath testing can predict BE and to validate its performance in independent cohorts including participants with BE, participants with GERD, and controls. Participants aged ≥18 years referred for gastroscopy between August 2017 and July 2022, were eligible for inclusion. The diagnostic accuracy of VOC breath testing was assessed using four machine learning algorithms (MLAs): (1) random forest, (2) extremely randomized trees, (3) eXtreme Gradient Boosting (XGBoost), and (4) convolutional neural network. Patient tolerability and patient acceptability of breath testing were secondary outcome measures. A total of 1079 participants were included, 602 (55.8%) in the training cohort and 477 (44.2%) in the validation cohort. In the training cohort, XGBoost was the best performing MLA in differentiating BE from GERD and controls (area under the receiver operating characteristic [AUROC] 0.892 [95% CI, 0.862–0.921]). However, in the validation cohort, the performance of XGBoost markedly declined (AUROC 0.530 [95% CI, 0.472–0.589]). Median tolerability score was 2.00 with 0 ‘no discomfort’ and 10 ‘worst discomfort imaginable’, and median acceptability score was 8.00 with 0 ‘worst experience’ and 10 ‘best experience’. VOC breath testing in its current form does not provide additional diagnostic value for BE screening; however, based on the high degree of patient acceptability, further research on eNose technology seems justified.

    2026
    引用
    AI阅读
    加入学术空间
    3Management of T1b Esophagogastric Adenocarcinoma: Interpreting the CONGRESS Study
    Yuto Shimamura,Vani J A Konda
    2026
    引用
    AI阅读
    加入学术空间
    4Endoscopic Eradication Therapy of Barrett's Dysplasia and Early Adenocarcinoma: Where We Stand and What's Next
    Vijayvardhan Kamalumpundi,Andreas Hadjinicolaou,Massimiliano Di Pietro,Cadman L. Leggett

    Barrett's esophagus (BE) is the only recognized precursor to esophageal adenocarcinoma (EAC). Endoscopic monitoring of BE allows for early detection and prevention against advanced cancer, which carries high morbidity and mortality. Over the past two decades, management of early EAC has shifted from esophagectomy toward organ-preserving endoscopic eradication therapy (EET), including endoscopic mucosal resection (EMR), endoscopic submucosal dissection (ESD), and ablative modalities such as radiofrequency ablation, cryotherapy, and hybrid argon plasma coagulation. EMR remains standard for most lesions with pre-invasive neoplasia and small intramucosal EAC, while ESD provides technical advantages for larger or complex neoplasia, though comparative long-term outcome data are limited. Ablation after resection achieves durable clearance of dysplasia and intestinal metaplasia, with emerging therapies showing promise in refractory or high-risk cases. Structured post-EET surveillance is critical, as recurrence risk is highest within 1-2 years of achieving remission, but persists at lower levels long-term. The risk of recurrence is influenced by lesion characteristics, treatment strategy, and center experience. Personalized, risk-adapted surveillance is increasingly supported, incorporating clinical factors such as BE length, baseline histology and prior treatment. More recently, molecular biomarkers and artificial intelligence (AI)-driven integration of clinical and genomic features have shown promising results. Future research should optimize tissue acquisition, refine biomarker panels, and validate AI-enabled predictive models to improve patient selection, minimize recurrence, and guide cost-effective, individualized care.

    2026
    引用
    AI阅读
    加入学术空间
    5Lessons Learned from a Decade of EUS(-FNA) Staging in Esophageal and GEJ Carcinoma: Towards a Selective Staging Strategy.
    J. Quik, J. V. van Sandick, E. Owers,A. Bartels-Rutten, F. Voncken, L. Kodach, T. R. de Wijkerslooth, J. V. van Dieren, J. Ijspeert
    2026
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 7382 篇论文

    高被引作者

    作者引用发文
    Richard Van Hillegersberg177397
    Sheraz Markar167773
    Mark Van Berge Henegouwen1581144
    Jelle Ruurda137565
    Donald E Low119836
    Hubert J. Stein115540
    Longqi Chen112754
    Lars Lundell109622
    Attila Csendes103519
    John V. Reynolds102679

    高产作者

    作者引用发文
    Mark Van Berge Henegouwen1581144
    Suzanne Gisbertz83098
    Richard Van Hillegersberg177397
    John V. Reynolds102679
    Sheraz Markar167773
    Camiel Rosman55671
    Jelle Ruurda137565
    B.P.L. (Bas) Wijnhoven59959
    Bonavina Luigi77156
    Magnus Nilsson42155

    相关期刊

    Diseases of the colon and rectum
    Digestive surgery
    Journal Of Hepato-Biliary-Pancreatic Sciences
    Esophagus
    Annals of coloproctology
    Annals of gastroenterological surgery
    HPB
    Journal of Gastrointestinal Surgery
    Clinics in Colon and Rectal Surgery
    Annals of Surgical Treatment and Research